Introduction
============

Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) is a high-precision radiotherapy technique that utilises high doses of radiation in a few or single fractions for the treatment of small to moderate extra-cranial tumours.

Recent technological advancements in immobilisation, imaging and the ability to compensate for respiratory motion have led to an increase in the use of SBRT in a number of clinical settings.

SBRT is an emerging and evolving treatment modality where optimal dose, fractionation schedule and technique are still to be determined. However, early results of studies utilising SBRT for the treatment of inoperable early stage non-small cell-lung cancer (NSCLC) and spinal metastases have shown favourable results.[@b1] SBRT has also been used for the treatment of other extra-cranial tumours like prostate cancer, liver metastasis, unresectable pancreatic cancer and other abdominal lesions.[@b2],[@b3] Limited experience in these studies suggests favourable local tumour control results.

However, many conformal SBRT/SABR studies have reported frequently occurring and clinically significant treatment related toxicity complications.[@b4] Another drawback associated with SBRT is the long treatment times relating to patient setup and radiation delivery. Depending on equipment and dose utilised, patient setup time can take up to 22 min[@b5] and 100 min for treatment delivery.[@b6] Longer treatment times significantly increase the chances of intrafraction motion and error.[@b7]

Recently there has been much interest at mitigating the risks associated with SABR by delivering stereotactic doses through different techniques other than static non-coplanar/planer beams, most notably these include the use of SBRT with intensity modulated therapy (IMRT),[@b8],[@b9] volumetric modulated arc therapy (VMAT)[@b10]--[@b12] also referred to as rapid arc (RA) and or other arc-related treatment techniques such as cyberknife.[@b13]

The purpose of this review was to assess the feasibility of emerging VMAT and IMRT-based SBRT treatment techniques. Furthermore, we aimed to identify any emerging and advantageous SBRT planning trends and in particular see which SBRT planning modality offered the best outcome for prospective patients.

Method
======

A review and synthesis of data from the current literature up to September 2013 was conducted on EMBASE, PubMed, Science Direct, Google Scholar, Proquest central, Medline and the Cochrane Database of Systematic reviews. A combination of relevant keywords and subject headings were used as shown in Figure[1](#fig01){ref-type="fig"}. No time or language restriction was applied. Articles that included SBRT with the words modulated, IMRT and or VMAT were all considered. For an article to be included, it firstly had to be a full text article and relate to SBRT/SABR. It then had to compare IMRT and VMAT dose distribution plans and or delivery times to each other, or evaluate SBRT VMAT/IMRT plans with other current SBRT treatment modalities which included: 3D conformal radiotherapy (3DCRT), Cyberknife or VMAT flattening filter free (FFF). Any SBRT studies that utilised VMAT and or IMRT that reported clinical outcomes of local control and or survival outcomes were also included. Notably a large amount of (36) supplementary articles and conference posters relevant to the research topic were excluded based on the limited data presented. Due to limited amount of full text data relating to this specific data, all papers that were considered eligible (21) were screened by all three authors to limit bias.
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Studies were analysed based on treatment times, organ dose, monitor units, conformity index, planning techniques and where applicable local tumour control and survival outcomes. Studies that were included reported at least three of these variables. A summary of the search methodology can be seen in Figure[1](#fig01){ref-type="fig"}.

Results
=======

A search of the literature yielded 385 articles, of these 21 full text articles were retrieved and analysed against the inclusion criteria, with 10 studies included in the final analysis (Fig[1](#fig01){ref-type="fig"}). From these, five studies[@b14]--[@b17],[@b8] related to medically inoperable stage 1 and 2 NSCLC (T1-T2NOMO), three cases[@b8]--[@b10] related to spinal metastases, with two directly comparing VMAT SBRT to IMRT SBRT the other comparing VMAT FFF SBRT to VMAT with flattening filter (FF) SBRT.[@b8] One study[@b11] looked at the feasibility of VMAT/IMRT SBRT to that of 3DCRT for the treatment of abdominal lymph node malignancies, and another reviewed the feasibility of IMRT/VMAT SBRT for the treatment of pancreatic adenocarcinoma.[@b12] All the articles included in the review reported on a minimum of six dosimetric planning or treatment outcomes, articles with \<6 dosimetric results were deemed not to provide an acceptable level of data for a qualitative comparison and not included in this review.

Use of VMAT and IMRT for SBRT in medically inoperable lung lesions
------------------------------------------------------------------

Five lung cancer studies[@b14]--[@b17],[@b8] were analysed and categorised in Table[1](#tbl1){ref-type="table"}. Unfortunately not all the studies presented the same variables; however, at least three common variables were reported throughout the studies which were used for comparison. Of the studies reviewed, only two SBRT studies[@b16],[@b18] that utilised VMAT and or IMRT reported clinical outcomes of local control or survival outcomes. Both these studies related to medically inoperable NSCLC (T1--T2NOMO). The earlier of these two studies[@b18] utilised 7 beam IMRT SBRT for 25 peripheral lesions and 3 central lesions in 26 patients with a mean age of 24. The results of this study showed excellent local control and overall survival, where 3 year rates were 94.4% and 52% respectively. Median survival was 38.4 months. The latter of these studies[@b16] utilised VMAT RA FFF and retrospectively compared results to previous patients treated with 3DCRT with the same dose and fractionation schedule. This is the only study to date that has presented clinical results of VMAT RA FFF for lung SBRT. The 1 year local control rate for VMAT compared to 3DCRT was 100% and 92.5% respectively. Analysis of pulmonary toxicity favoured the VMAT RA FFF cohort where: there were eight accounts (17.4%) of grade 1-grade 2 (G1-G2) and 2 accounts (4%) of grade 3 (G3) pulmonary toxicity. In comparison, the rate of G1, G2 and G3 pulmonary toxicity for the 3DCRT cohort was 24%, 42% and 9% respectively. The low pulmonary toxicity rate seen in the VMAT RA FFF cohort correlated with a decreased percentage in V~20~ and V~5~ lung dose for VMAT RA FFF patients. Of the five studies, two planning studies[@b14],[@b17] directly compared VMAT to IMRT; in both studies, treatment time was reduced by an average of 70% with VMAT to that of IMRT. The average dose to healthy lung V~20~ between VMAT and IMRT in both studies was comparable with only a 0.3%[@b14] and 0.2%[@b17] difference respectively. Lung V~5~ dose was slightly higher in the VMAT cohort in both studies -- 1.4%[@b14] and 3.7%[@b17] respectively.

###### 

Summary of dosimetric results for studies utilising IMRT and VMAT SBRT in medically inoperable stage 1 NSCLC

  Reference                   Holt et al.[@b14]                         Ong et al.[@b17]                                                                                                Navarria et al.[@b16]                 McGrath et al.[@b15]                   Ong et al.[@b8]                                                                                                                                                                                                                 
  --------------------------- ----------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------- -------------------------------------- ------------------------------------------------------------ ----------------------------------- ------------------------------ ---------------------------- --------------------------- ---------------- --------------------- ---------------------
  Target area                 Medically inoperable NSCLC (T1--T2NOMO)   Medically inoperable stage 1 NSCLC                                                                              Medically inoperable stage 1 NSCLC    Medically inoperable stage 1A NSCLC    Medically inoperable stage 1 NSCLC                                                                                                                                                                                              
  Dose/Fx                     54 Gy/3Fx (18 Gy/Fx)                      (60 Gy/8Fx), (55 Gy/5Fx), (54 Gy/3F) (Results for delivery time represent delivery of single 7.5 Gy fraction)   48 Gy/4Fx (12 Gy per Fx)              48 Gy/4Fx (12 Gy/Fx)                   3 Fractionation schemes (54 Gy/3Fx), (55 Gy/5Fx), (60/8Fx)                                                                                                                                                                      
  Variable                    VMAT                                      IMRT (coplanar)                                                                                                 VMAT RA                               IMRT sliding window (coplanar)         VMAT RA                                                      3DCRT                               VMAT RA with FFF               3DCRT FF                     VMAT                        3D-CRT           VMAT RA FF 6MV        VMAT RA FFF 10MV
  Patients                    27                                        9                                                                                                               18                                    46                                     86                                                           21                                  10                                                                                                                             
  Arc length/beam number      1 dual arc of 209°                        12--16                                                                                                          2 × 358°                              9--10                                  2 × 358°                                                     10                                  1--2 × 212 ± 37°               4--6 × 360° conformal arcs   1 × 180°                    7--10            2 × 360°              2 × 360°
  Mean PTV (cm^3^)            44.5 (range 14.3--101.8 cm^3)^            27.1 ± 13.4 (range 11.9--55.8 cm^3^)                                                                            38.8 ± 21.3 (range 6.3--67.1 cm^3)^   46.7 ± 27.7 (range 2.3--125.2 cm^3^)   59.9 ± 7.7 (range 6.1--162.2 cm^3)^                          57.4 cm (range 22.2--125.2 cm^3^)   58.2 (rage 8.9--153.4 cm^3^)                                                                                                   
  Delivery time (min)         6.6                                       23.7                                                                                                            3.9                                   12                                     3.9                                                          11.6                                1.5 ± 0.3                      8.3 ± 1.3                    6.1                         11.9             3.6 ± 1.0             2.5 ± 0.1
  0.66                        0.82                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Lung V~5~ (%)               18                                        19.4                                                                                                            17 ± 7.7                              14.7 ± 6.9                             18.3 ± 7.2                                                   18.1 ± 6.8                          25.3 ± 11.8                    31.4 ± 11.9                  VMAT plan \< V~5~ by 4.2    NA               NA                    
  Lung V~20~ (%)              5.4                                       5.7                                                                                                             4.4 ± 2.7                             4.2 ± 2.5                              5.4 ± 3.2                                                    4.9 ± 2.9                           7.3 ± 4.9                      11.8 ± 7.0                   VMAT plan \< V~20~ by 4.5   NA               NA                    
  Spinal cord *D*~max~ (Gy)   *D*~max~ 8.3                              *D*~max~ 8.1                                                                                                    NA                                    NA                                     10.8 ± 5.0                                                   7.9 ± 3.8                           NA                             NA                           *D*~max~ 11.46              *D*~max~ 11.78   *D*~max~ 13.5 ± 5.3   *D*~max~ 13.4 ± 5.4
  Chest wall                  36.2 V~30Gy~(cm^3^)                       36.1 V~30Gy~(cm^3^)                                                                                             8.6 ± 12.2 V~30Gy~(cm^3^)             24.8 ± 11.5 V~30Gy~(cm^3^)             1.2 ± 1.8 V~45Gy~(cm^3^)                                     2.0 ± 2.7 V~45Gy~(cm^3^)            NA                             NA                           NA                          NA               NA                    NA
  MUs                         3428~Mus/1\ Fx\ of\ 18Gy~                 3335~Mus/1\ Fx\ of\ 18Gy~                                                                                       234 ± 27~MU/Gy~                       445 ± 84~MU/Gy~                        240 ± 31~MU/Gy~                                              179 ± 18~MU/Gy~                     1907 ± 632~MU/min~             300~MU/min~                  2360~mean~                  2235~mean~       228 ± 18~MU/Gy~       247 ± 26~MU/Gy~
  CI~80~                      NA                                        NA                                                                                                              1.07 ± 0.02                           1.14 ± 0.06                            1.10 ± 0.07                                                  1.18 ± 0.12                         NA                             NA                           1.87                        1.93             1.08 ± 0.3            1.08 ± 0.4
  CI~50~                      5.17                                      5.31                                                                                                            NA                                    NA                                     NA                                                           NA                                  NA                             NA                           5.19                        5.65             1.97 ± 0.18           1.99 ± 0.20

MU, monitor units; PTV, planning target volume; NSCLC, non-small-cell lung cancer, IMRT, intensity modulated radiotherapy; VMAT, volumetric modulated arc therapy; 3DCRT, 3D conformal radiotherapy therapy; RA, rapid arc; FF flattening filter; FFF, flattening filter free; *D*~max~, maximum dose; CI, conformity index; Fx, fraction; *V*~*n*~, volume of lung receiving n dose in Gy; NA, not applicable.

Three studies compared VMAT-SBRT with 3DCRT-SBRT,[@b15]--[@b17] one of which utilised VMAT FFF.[@b16] Between the three studies VMAT reduced the average treatment time by 66%, mean lung V~5~ by 8.1% and mean lung V~20~ by 11.2%. However, one of these studies[@b17] reported a slight increase in lung V~20~ with VMAT and no significant difference (NSD) in lung V~5~ dose. All three studies reported an improvement with VMAT in plan conformity[@b15],[@b17] and or homogeneity[@b16] compared to 3DCRT.

Finally one plan directly compared VMAT FF SBRT with VMAT FFF SBRT. Patients planed with FFF had a reduction in treatment delivery time by 31% whilst maintaining comparable plan quality. There was NSD in rib dose between the two modalities or any other reported organs at risk (OAR). However, the average monitor units (MU)/Gy needed was 8% higher with the FFF plans.

Use of VMAT and IMRT for stereotactic spine radiotherapy
--------------------------------------------------------

The use of VMAT and IMRT for the delivery of SBRT in spinal metastasis was analysed in three retrospective studies.[@b8]--[@b10] The dosimetric results of these studies were analysed and categorised accordingly in Table[2](#tbl2){ref-type="table"}. The earliest of these studies[@b10] compared IMRT SBRT to VMAT SBRT with 1 and 2 arcs. The number of multi-leaf collimator (MLC) segments needed for the IMRT plans was 1131 ± 183. Compared to VMAT~1arc~ (177) and VMAT~2arc~ (354), the number of segments was considerably higher for the IMRT plans. Projected delivery time was reduced by 50% and 46% with the use of VMAT SBRT for 1 and 2 arcs respectively. A similar correlation was seen with a reduction in mean MUs by 11% and 27% with 1 and 2 arcs respectively. However, these results could not be replicated to the same extent with the study conducted by Kuijper et al.,[@b9] where the delivery time for both IMRT and VMAT was comparable for 2 arcs and only slightly faster (18%) for 3 arcs compared to IMRT. There was NSD in planning target volume (PTV) coverage in all three studies. Spinal cord sparing was comparable between the studies but worst with VMAT using 1 arc.[@b10] Plan conformity was the greatest in both studies utilising 2 arcs.[@b9],[@b10] The application of VMAT FFF SBRT reduced projected radiation delivery time by 58% compared to standard VMAT SBRT without compromising plan accuracy or quality.[@b8]

###### 

Summary of dosimetric results for studies utilising IMRT and VMAT SBRT for spinal metastasis

  Reference                        Wu et al.[@b10]                    Kuijper et al.[@b9]         Ong et al.[@b8]                                                                                                                                                                 
  -------------------------------- ---------------------------------- --------------------------- ------------------------------------ --------------------------------------- ---------------------------------------- ------------------ ------------------ ------------------- -------------------
  Target area                      Spinal metastasis                  Spinal metastasis           Spinal metastasis                                                                                                                                                               
  Dose/Fx                          16 Gy/1Fx                          16 Gy/1Fx                   16 Gy/1Fx or 10 Gy/2Fx or 9 Gy/3Fx                                                                                                                                              
  Variable                         IMRT                               VMAT 1 arc                  VMAT 2 arcs                          *Vertebral body* *IMRT VMAT* *2 arcs*   *Entire vertebra* *IMRT VMAT* *3 arcs*   VMAT RA FF 6MV     VMAT RA FFF 10MV                       
  Patients                         10                                 3                           4                                    10                                                                                                                                         
  Arc length/beam number           8--12                              1 × 358°                    2 × 358°                             7--9                                    2 × 358°                                 7--9               3 × 358°           2 × 360°            
  Mean PTV (cm^3^)                 104.56 (range 11.5--411.1 cm^3^)   109 (range 82--147 cm^3^)   181 (range 109--331 cm^3^)           119 (range 34.13--225.9 cm^3^)                                                                                                             
  Delivery time (min)              15.9                               7.9                         8.6                                  12.5                                    13.5                                     19.5               16                 6.7 ± 2.7           2.8 ± 0.4
  PTV *D*~mean~                    16.7 ± 0.13                        16.7 ± 0.20                 16.7 ± 0.18                          18.7                                    18.3                                     17.5               17.3               112 ± 4 (%)         114 ± 4 (%)
  PTV D~95%~                       15.5 ± 0.15                        15.6 ± 0.16                 15.5 ± 0.15                          16                                      16                                       14.2               14.5               NA                  NA
  Lung V~5~                        130 ± 84                           166 ± 104                   164 ± 104                            NA                                      NA                                       NA                 NA                 NA                  NA
  Lung V~10~                       35 ± 22                            45 ± 27                     43 ± 26                              NA                                      NA                                       NA                 NA                 NA                  NA
  Spinal cord *D*~max/mean~ (Gy)   *D*~mean~ 4.48 ± 0.87              *D*~mean~ 5.21 ± 0.92       *D*~mean~ 4.81 ± 0.81                *D*~max~ 8.5                            *D*~max~ 8.3                             D~max~ 9.7         D~max~ 9.2         D~max~ 13.5 ± 5.3   D~max~ 13.4 ± 5.4
  Spinal cord D~10~                6.65 ± 1.05%                       7.75 ± 1.05%                6.97 ± 0.91%                         3.6%                                    3.6%                                     11.5%              9.4%               NA                  NA
  Oesophagus *D*~mean~             5.85 ± 2.48                        5.34 ± 2.64                 5.37 ± 2.45                          4.5                                     5.0                                      6.4                6.7                NA                  NA
  Skin *D*~max~ Gy                 NA                                 NA                          NA                                   NA                                      NA                                       NA                 NA                 11.1 ± 5.0          10.9 ± 4.9
  MUs                              Mean + (SD) 8711 ± 1308            Mean + (SD) 7730 ± 1843     Mean + (SD) 6317 ± 1156              Mean + (SD) 5660                        Mean + (SD) 7816                         Mean + (SD) 9399   Mean + (SD) 9019   528 ± 113MU/Gy      498 ± 91 MU/Gy
  CI~avg~                          1.15 ± 0.06                        1.12 ± 0.04                 1.09 ± 0.03                          1.10                                    1.02                                     1.10               0.90               NA                  NA

MU, monitor units; PTV, planning target volume; IMRT, intensity modulated radiotherapy; VMAT, volumetric modulated arc therapy; 3DCRT, 3D conformal radiotherapy therapy; RA, rapid arc; FF, flattening filter; FFF, flattening filter free; *D*~max~, maximum dose; SD, standard deviation; CI, conformity index; Fx, fraction: *V*~*n*~, volume of lung receiving *n* dose (Gy); NA, not applicable; *D*~xx%~, dose (Gy) to xx% of volume.

Use of VMAT and IMRT for SBRT in abdominal lymph node metastases and pancreatic adenocarcinoma
----------------------------------------------------------------------------------------------

One retrospective planning study evaluated the feasibility of VMAT and IMRT for SBRT in abdominal lymph node metastases on a patient cohort previously treated with SBRT, using 3DCRT techniques.[@b11] The dosimetric results of this study are presented in Table[3](#tbl3){ref-type="table"}. Review of these results demonstrated: Effective treatment time increased by 41% with IMRT and decreased by 42% with VMAT compared to 3DCRT. VMAT significantly improved PTV~95(%)~ coverage by a rate of 9% and conformality was greatest with VMAT and slightly less with IMRT compared to that of 3DCRT. In relation to OARs and dose to healthy tissue IMRT and VMAT showed superior healthy tissue sparing to that of CRT. The rate of improvement for IMRT and VMAT respectively in the following parameters are as follows: healthy tissue V~10~ Gy (%): 37% and 51%, spinal cord *D*~max(Gy)~: NSD and 30%, small bowel D~1~% (Gy):17% and 22%, spinal cord D~1~% (Gy): 22% and 40% and mean liver dose NSD and 16%.

###### 

Summary of dosimetric results for SBRT planning study comparing 3DCRT versus IMRT versus VMAT--RA for the treatment of abdominal metastasis

  Reference                                        Bignardi et al.[@b11]                                                                            Kumar et al.[@b12]                                                                 
  ------------------------------------------------ ------------------------------------------------------------------------------------------------ ------------------------------------ -------------------------- ------------------ ------------------
  Target area                                      Lymph nodes (abdominal region) 45 Gy/6Fx                                                         Locally advanced pancreatic cancer                                                 
  Dose/Fx                                          Plans acceptable if PTV dose \>36 Gy (spinal cord 53 ± 21 cm^3^) (small bowel 780 ± 633 cm^3^)   25 Gy/1Fx                                                                          
  Variable                                         3DCRT                                                                                            IMRT (co-planar)                     VMAT RA                    DS VMAT            DS IMRT
  Patients                                         14                                                                                               15                                                                                 
  Effective treatment time (min)                   6.3 ± 0.5                                                                                        10.6 ± 1.2                           3.7 ± 0.4                  9                  11.45
  PTV: mean volume (cm^3^)                         44.0 ± 0.4                                                                                       44.26 ± 0.4                          44.5 ± 0.3                 135                135
  PTV V~95~ (%)                                    82.5 ± 9.6                                                                                       84.5 ± 8.2                           90.2 ± 5.2                 97.5               98.6
  Healthy tissue V~10~Gy (%)                       6.3 ± 4.4                                                                                        4.0 ± 1.9                            3.1 ± 1.81                 NA                 NA
  Healthy tissue integral dose (Gy cm^3^ 10^−5^)   NA                                                                                               NA                                   NA                         0.37               0.35
  Healthy tissue CI~60%~                           3.8 ± 1.49                                                                                       3.2 ± 0.7                            2.5 ± 0.3                  NA                 NA
  Left kidney V~5\ Gy~ (%)                         NA                                                                                               NA                                   NA                         7.6                17.6
  Small bowel D~1%~ (Gy) or D~1cc~ (Gy)            D~1%~ (Gy) 23.02 ± 10.81                                                                         D~1%~ (Gy) 19.01 ± 11.50             D~1%~ (Gy) 18.01 ± 10.83   D~1cc~ (Gy) 24.7   D~1cc~ (Gy) 25.6
  Small bowel V~36Gy~ or V~20\ Gy~ (%)             V~36Gy~ 0.3 ± 0.7                                                                                V~36Gy~ 0.2 ± 0.4                    V~36Gy~ 0.1 ± 0.2          V~20\ Gy~ 18.8     V~20\ Gy~ 21.9
  Spinal cord *D*~max~ (Gy)                        13.7 ± 5.7                                                                                       13.9 ± 3.2                           9.6 ± 2.3                  11.6               11.7
  Spinal cord D~1~% (Gy) or V~5\ (Gy)~             D1% (Gy) 12.9 ± 5.9                                                                              D1% (Gy) 10 ± 2.8                    D1% (Gy) 7.8 ± 2.3         V~5\ (Gy)~ 22.2    V~5\ (Gy)~ 23.8
  Liver mean (Gy)                                  4.3 ± 4.3                                                                                        3.8 ± 4.0                            3.6 ± 3.9                  2.8                2.5
  MUs                                              1554 ± 153                                                                                       2583 ± 699                           2186 ± 211                 5437               6894

MU, monitor units; PTV, planning target volume; IMRT, intensity modulated radiotherapy; VMAT, volumetric modulated arc therapy; 3DCRT, 3D conformal radiotherapy therapy; RA, rapid arc; *D*~max~, maximum dose; SD, standard deviation; CI, conformity index; Fx, fraction; DS, dose sparing; *V*~*n*~, volume of tissue receiving *n* dose (Gy); NA, not applicable; *D*~xx%~, dose (Gy) to xx% of volume.

The use of IMRT SBRT to that of VMAT SBRT for the treatment of locally advanced pancreatic adenocarcinoma was also compared in a retrospective planning study of 15 patients.[@b12] The dosimetric parameters summarised in Table[3](#tbl3){ref-type="table"} for both plan types were similar. There was, however, a significant improvement in dose sparing with VMAT compared to IMRT to the spinal cord V~5~ ~Gy~ dose (*P* \< 0.001) and the left kidney dose measured by *D*~mean~ (*P* \< 0.001), V~5Gy~ and D~25%~. Treatment time and MU utilised were both reduced by 21% with VMAT. In retrospect IMRT showed superior *D*~mean~ dosimetric parameters for the liver (*P* \< 0.003) and stomach (*P* \< 0.05) respectively. There was also a notable trend observed between PTV size and volumetric sparing of the duodenum; that is as the PTV size increased or overlapped into healthy tissue, the ability for both IMRT and VMAT SBRT to spare the duodenum decreased. We further examined this relationship and found in the two lung[@b14][@b17] and spinal[@b9][@b10] studies that utilised the same treatment parameters within their cohort, the ability to spare healthy surrounding OAR such as healthy lung and oesophagus decreased as the PTV size increased, measured by lung V~20~ and oesophagus *D*~mean~ respectively.

Discussion
==========

Lung cancer
-----------

For patients with stage 1 NSCLC, surgical resection offers the best 5 year survival outcome of 60--70%.[@b19] However, for patients with medically inoperable NSCLC who have undergone 3DCRT with standard fractionation and doses typically 45--60 Gy in 1.8--2.0 Gy/Fx over 6 weeks, the 5 year survival rate is only 10--30%.[@b20] The use of SBRT for the treatment of medically inoperable stage 1 NSCLC has seen some more favourable results. The results of SBRT are notably illustrated by two prospective phase ll studies: The Radiation Therapy Oncology Group (RTOG 0236)[@b21] and The Nordic Cooperative Group (NCG).[@b22] Both studies investigated SBRT for peripheral stage 1 T1T2N0M0 tumours which were treated with 54 Gy/3Fx (RTOG 0236) or 45 Gy/3Fx (NCG), local control and overall survival for the RTOG 0236 trial at 3 years were reported to be 91% and 48% (T1N0M0) and 56% (T2N0M0) respectively, grade 3 and 4 treatment-related toxicity was seen in 28% of patients. The NCG group reported 3 year local control and overall survival to be 92% and 60% (T1N0M0) and 88% (T2N0M0) respectively.

As with the above studies, SBRT is most commonly employed using multiple static beams where treatment delivery can take up to 100 min.[@b6] As treatment time increases so does the probability of tumour shifts from that of the initial setup. Recent evidence suggests that longer treatment times increase the rate of secondary cancers which are associated with cell repopulation during treatment.[@b23] Faster application of SBRT possibly through VMAT, could therefore improve patient comfort, treatment accuracy and patient outcomes. Of the studies reviewed, VMAT FFF offered the greatest time improvement for both VMAT versus IMRT and VMAT versus CRT. Uncertainties in tumour position caused by intra-fractional motion have been of concern for SBRT treatments. However, adaptation of breath hold techniques with Active Breathing Coordinator™ (ABC; Elekta, Stockholm, Sweden) has been shown to reduce intra-fractional motion uncertainty, this was demonstrated in a prospective phase I/II study by the group at Royal Marsden Hospital in London,[@b24] which have successfully used the combination of cone beam computer tomography, VMAT and ABC to reduce overall treatment time of lung SBRT and significantly reduce dose to healthy lung.

Proximal lesions (tumours that are within 2 cm of the proximal bronchial tree) have also been treated with SBRT with reasonable results; however, they have been associated with a larger degree of treatment-related toxicity.[@b1] Patients with central tumours compared to those with peripheral tumours have a 11-fold higher risk of developing severe toxicity.[@b1] Factors such as increased mean dose to the ipsilateral lung and V~5~ (%) of the contralateral lung have been associated with the development of radiation pneumonitis.[@b2] In the studies that compared VMAT to 3DCRT two[@b15],[@b16] of these saw significant reductions in lung V~5~ and lung V~20~; however, the third study[@b17] did not show a significant difference in lung V~5~ and showed better volume sparing for lung V~20~ in the 3DCRT cohort. However, in this study, the plans were optimised for chest wall sparing which resulted in increased lung dose. The results of these studies indicate that VMAT is a suitable alternative to 3DCRT SBRT for the treatment of medically inoperable NSCLC.

Spine
-----

Spinal metastasis and spinal cord compression is commonly treated with conventional anterior posterior (AP) posterior anterior (PA) RT techniques; however treatment outcomes of conventional techniques have been sub-optimal.[@b25] SBRT studies[@b26] have shown significant improvements in pain management and long-term control. A prospective RTOG trial[@b27] is currently further examining the feasibility of spinal SBRT. The planning of spinal SBRT requires steep dose constraints and a highly conformal dose distribution around the PTV which surrounds the spinal cord. One of the main complications of 3DCRT spinal SBRT treatment is radiation myelopathy,[@b4] a recently developed logistic model has recommended a number of dose constraints to the thecal sac to maintain radiation myelopathy under 5%: The *D*~max~ to the thecal sac for a single fraction should be no more than 12.4 Gy, for 2 fractions 17 Gy, 20.3 Gy for 3 fractions and 23.0 Gy for 4 fractions.[@b28] In comparison, all three spinal studies reviewed[@b8]--[@b10] were able to maintain this dose constraint whilst meeting 3DCRT SBRT planning constraints.

Closer analysis of the spinal studies suggests as first proposed by Wu et al.[@b10] that there is a correlation between the number of MLC segments and the dose drop-off rate within the cord. Intensity map manipulation is inadvertently affected by the number of segments in a beam and therefore more segments allows for finer intensity manipulation and a sharper dose gradient at the PTV spinal cord junction. As reported earlier, VMAT utilises fewer segments than IMRT but this increases with the number of arcs, in the spinal studies analysed although cord dose was comparable, cord sparing improved when more arcs were implemented. Based on analysis of these results, it could be suggested that at least 2 arcs should be used for future planning and treatment studies, however higher doses may require 3 arcs to avoid delivery times \>3 min per arc.[@b9] All FFF vertebral plans required only 2 arcs.

There has been some concern that the use of FFF beams can increase the dose at the build-up regions due to an increase in lower mean energy from the lack of beam hardening.[@b29] Ong et al.[@b8] compared skin doses between 6-MV FF and 10-MV FFF and found no significant increase to skin dose.

An observed relationship throughout the studies utilising VMAT was the collimator angle used. Several studies[@b8],[@b9],[@b11] reported the use of a collimator angle between 30° and 45°; Kuijper et al.[@b9] suggested a collimator range of 30--45° achieved optimal sparing.

Lymph node lesions and pancreatic adenocarcinoma
------------------------------------------------

The use of SBRT for the treatment of metastatic abdominal malignancies is very limited nevertheless recent results[@b13] have shown improvement in local control and improved quality of life; however, studies such as these have been limited to the use of cyberknife.[@b13] Results of the retrospective planning study reviewed, showed favourable outcomes for the use of IMRT and VMAT for the delivery of SBRT in abdominal malignancies.[@b11] Most notably was the improvement in treatment time efficiency, conformality and reduction in dose to OAR. Organ motion relating to nodes in the hepatic hilus is still a concern; one solution is the implementation of an ABC technique in combination with VMAT FFF in patients who can hold their breath for 15 sec. Centres that do not have access to ABC could feasibly treat retroperitoneal nodes bordering large vessels effectively due to the limited organ motion in these areas.[@b11] A current multicentre prospective study with VMAT-RA as the treatment modality should establish a more conclusive understanding of VMAT-FF treatment efficacy in this line of patients.

The use of SBRT for the treatment of unresectable pancreatic adenocarcinoma was studied by Kumar et al.,[@b12] with the exception of spinal cord *D*~max~ both IMRT/VMAT SBRT were able to obtain the normal tissue constraints used for treatment planning constraints utilised in previous Cyberknife studies.[@b30]

One of the main concerns in previous studies such as the one conducted by Chang et al.[@b30] is treatment-related toxicity; however, the dosimetric parameters presented by Kumar et al.[@b12] suggest advantageous dosimetric sparing to that of Cyberknife SBRT, specifically significant reductions in kidney, stomach and liver dose. VMAT SBRT offered significant improvements in treatment time and MU over the other modalities.

Similar to the findings of Kumar et al.,[@b12] we suggest a relationship between PTV size and the ability to spare healthy tissue. As the PTV size increases for both IMRT and VMAT, efficiency of volumetric sparing of healthy tissues decreases. We suggest future studies look at this relationship in more detail.

Limitations
===========

Limitations of this review included the small population numbers in some of the studies reviewed and some studies did not present the same comparative parameters. Where adequate data were given, we tabulated and recorded this in the appropriate tables. As data for large SBRT studies are only recently emerging, future studies should look at the trends presented in these studies in more detail when developing clinical guidelines. Future studies should also place a greater emphasis on survival and toxicity outcomes between SBRT treatment modalities, specifically assessing planning constraints like number of arcs used and length of delivery time to that of late sequel side effects. This should result in the development of more defined planning constraints and guidelines for SBRT treatment modalities.

Conclusion
==========

In all the studies that were reviewed, the use of IMRT and VMAT for SBRT compared to 3DCRT SBRT showed improvements in dose conformality and homogeneity. Dose conformality was greatest with VMAT. Treatment time was markedly quicker with VMAT versus 3DCRT and IMRT in all cases except one. Overall both IMRT and VMAT were able to meet all planning constraints in the studies reviewed; however, treatment efficiency was greatest with VMAT. Notably cord sparing improved with a greater number of arcs, we suggest a minimum of 2 arcs be used for future planning and treatment studies. The relationship between PTV size and volumetric sparing efficiency should be further examined to form a conclusive understanding of this relationship. Overall VMAT and IMRT have been demonstrated as feasible alternatives to traditional static field RT SBRT.
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